INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Paper

Strategic Insights into Drug Regulatory Affairs: Dossier Preparation, Marketing Authorization, Variation and Safety Monitoring in Tanzania

Rutanshi Patel*[1], Gargi Patel[2], Dr. Maitreyi N. Zaveri[3], Zuki Patel[4]

[1]*M. Pharm, Department of Pharma Regulatory Affairs, K.B. Institute of Pharmaceutical Education and Research, a constituent college of Kadi Sarva Vishwavidyalaya, Gandhinagar*
[2]*Industrial guide, Acme Pharmaceuticals, Ahmedabad*
[3]*Head of Department, Pharma Regulatory Affairs, K.B. Institute of Pharmaceutical Education and Research, a constituent college of Kadi Sarva Vishwavidyalaya, Gandhinagar Acme Pharmaceuticals, Ahmedabad Head of Department of Pharma*
[4]*Assistant Professor, Pharma Regulatory Affairs, K.B. Institute of Pharmaceutical Education and Research, a constituent college of Kadi Sarva Vishwavidyalaya, Gandhinagar Acme Pharmaceuticals, Ahmedabad Head of Department of Pharma*

ARTICLE INFO

Published: 03 Apr. 2025
Keywords:
Strategic Insights, Drug Regulatory Affairs, Dossier Preparation, Marketing Authorization, Variation, Safety Monitoring
DOI:
10.5281/zenodo.15132665

ABSTRACT

Pharmaceutical regulatory affairs play a crucial role in ensuring drug quality, safety, and efficacy. This thesis, titled "Strategic Insights into Drug Regulatory Affairs: Dossier Preparation, Marketing Authorization, Variation, and Safety Monitoring in Tanzania", explores the regulatory landscape of the Tanzania Medicines and Medical Devices Authority (TMDA). It provides a comprehensive analysis of dossier preparation for drug registration, the marketing authorization process, post-approval variation management, and pharmacovigilance requirements in Tanzania.The study examines TMDA's regulatory framework, highlighting key requirements for medicinal product registration, renewal, and compliance with national and international guidelines. Through an in-depth review of variation classifications, submission processes, and regulatory timelines, this research identifies challenges encountered by pharmaceutical companies in maintaining compliance. Additionally, it emphasizes the importance of pharmacovigilance in post-market drug safety monitoring, outlining adverse event reporting mechanisms and risk management strategies.Findings from this study offer valuable insights for pharmaceutical professionals, regulatory authorities, and stakeholders seeking to navigate the Tanzanian regulatory environment efficiently.

***Corresponding Author:** Rutanshi Patel
Address: *M. Pharm, Department of Pharma Regulatory Affairs, K.B. Institute of Pharmaceutical Education and Research, a constituent college of Kadi Sarva Vishwavidyalaya, Gandhinagar*
Email ✉: rutu0402@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The thesis concludes with recommendations to enhance regulatory efficiency, reduce approval timelines, and improve compliance strategies to strengthen Tanzania's pharmaceutical sector.

INTRODUCTION

Regulatory affairs in the pharmaceutical industry serve as the backbone of drug development, ensuring that every medicinal product introduced to the market adheres to established safety, efficacy, and quality standards. In Tanzania, the regulatory landscape is governed by the TMDA, an authority responsible for overseeing drug registration, licensing, post-market surveillance, and compliance with Good Manufacturing Practices (GMP). As pharmaceutical companies navigate this complex regulatory framework, a deep understanding of dossier requirements, approval procedures, variation management, and pharmacovigilance becomes indispensable. This paper presents an in-depth examination of these regulatory elements, elucidating the stringent guidelines that shape the drug approval process in Tanzania. By analyzing regulatory trends and challenges, this study aims to equip industry stakeholders with the necessary insights to enhance regulatory efficiency and ensure successful market entry.

METHODOLOGY

This study is conducted through a detailed examination of TMDA guidelines, official regulatory documentation, industry case studies, and comparative analysis with international regulatory frameworks. A qualitative research approach is employed to evaluate the procedural intricacies involved in dossier preparation, marketing authorization, variation management, and pharmacovigilance. Primary data sources include regulatory filings, official reports from TMDA, World Health Organization (WHO) recommendations, and documented industry challenges. A case study methodology is also incorporated to highlight real-world implications of regulatory practices and provide a practical understanding of compliance challenges within the Tanzanian pharmaceutical sector. By synthesizing regulatory insights from multiple sources, this research aims to provide a holistic view of Tanzania's drug regulatory environment and identify key strategies to facilitate smoother regulatory submissions.

1. Regulatory Framework in Tanzania for New Product

1.1 Dossier Preparation

A well-structured dossier is the foundation of any successful drug registration process. In Tanzania, pharmaceutical companies are required to submit a Common Technical Document (CTD) that encompasses a wide range of data, including administrative details, pharmaceutical quality reports, preclinical findings, and clinical trial results. The CTD format is designed to ensure uniformity in regulatory submissions and facilitate efficient review processes. A robust dossier includes detailed descriptions of the drug's formulation, stability testing data, bioequivalence studies, Labelling information, and compliance with GMP standards. The stringent requirements demand meticulous documentation, as any deficiency in the dossier can lead to delays in approval or outright rejection. Pharmaceutical firms must, therefore, invest in regulatory expertise and thorough data compilation to align with TMDA expectations and streamline the registration process.

1.2 Requirement for Registration of Medicinal Product

Cover letter;
an appropriately filled-out application FORM MP A

medicinal product dossier
an authentic pharmaceutical product certificate
enough samples for one repeat analysis
site master file
un-refundable fees for application for GMP inspection

1.3 Evaluation of Medicinal Product



1.4 Marketing Authorization

Obtaining marketing authorization is a critical milestone in the lifecycle of a pharmaceutical product. The TMDA evaluates marketing authorization applications based on a rigorous assessment of safety, efficacy, and product quality. The process entails multiple regulatory steps, beginning with dossier submission and proceeding through an extensive review phase that scrutinizes compliance with Tanzanian and global regulatory standards. Companies seeking market entry must provide comprehensive evidence supporting the drug's therapeutic benefits, while also addressing any potential risks associated with its use. TMDA's regulatory framework is aligned with international best practices, yet the approval process can be time-consuming, particularly for new market entrants unfamiliar with local regulatory requirements. To expedite approvals, companies must proactively engage with TMDA regulators, ensure the accuracy of their submissions, and adopt a compliance-oriented approach to dossier preparation.

1.5 Fees for Registration of Medicinal Product

New Products			
Sr. No.	**Product category**	**Product type**	**Fees**
1.	Domestic manufactured	Human and veterinary medicines	1,000,000 TZS
2	Imported product	Human and veterinary medicines	2,000 USD

2. Regulatory Framework in Tanzania for Variation of Medicinal Product



Reporting Types for Variation

2.1 Reporting types

(a) Minor Variation: Minor variations are changes that may have minor effects on the overall safety, efficacy and quality of the FPP.

- Such variations can be implemented if no objection letter has been issued within three (3) months from the date of acknowledgement of receipt.

  Example: Change in Pack style of FPP

(b) Major Variation (Vmaj): Major variations are changes that could have major effects on the overall safety, efficacy and quality of the FPP.

Prior acceptance by TMDA is required before the changes can be implemented. A letter of acceptance will be issued for all major variations when the variation is considered acceptable. These variations will be handled within a time period of six (6) months from the date of acknowledgement of receipt.

Example: Change in the composition of a solution dosage form

(c) Immediate Notification: Such changes can be implemented immediately at the time of submission and they can be considered accepted if an objection is not issued by the Authority within two (2) months of the date of acknowledgement of receipt of the application.

Example: Change in the name or address of manufacturer of API

(d) Annual Notification: ANs should be submitted to TMDA within 12 months of implementation of the changes.

Example: The FPP's Standard was changed from an Internal to an official Pharmacopeial Standard

2.2 Documents required for the application for Variation

a variation application form, both as a Word document and a scanned signed PDF file, Replacement of the relevant sections of the dossier as per CTD format Copies of SmPC, PIL and labels, if relevant.

2.3 Evaluation of Variation



2.4 Fees for Authorization of Variation

Authorization of Variations			
Sr. No.	**Product category**	**Product type**	**Fess**
1.	Domestic manufactured	Major Variation	200,000 TZS
		Minor Variation	100,000 TZS
2.	Imported product	Major Variation	1000 USD
		Minor Variation	300 USD

3. Regulatory Framework in Tanzania for Renewal of Medicinal Product

Marketing authorizations validity: 5 years from the date of first issue. Renewal applications should be submitted to the TMDA at least (3) months or ninety (90) days before the expiry of the authorization. General Requirements for the application are as below:

1. Applications and documents must be in English; certified translations are required for other languages.
2. Applications must be complete and follow relevant human/veterinary pharmaceutical guidelines.
3. Submit a covering letter and application form in hard copy; dossiers should be on CD-ROM or electronically submitted.
4. Use A4-sized, 80g/m² paper, 12-point font, with sequentially numbered pages and properly referenced documents.
5. Provide two samples of the smallest commercial pack with batch certificates of analysis (COA).
6. Include proof of payment for non-refundable renewal fees as per TMDA regulations.
7. Submit evidence of GMP compliance for the manufacturing facility.
8. Provide a list of countries where the product has been approved during its registration

period, along with registration numbers and copies of certificates, if available

5.1 Fees for Renewal Application

Renewal Application			
Sr. No.	**Product category**	**Product type**	**Fees**
1.	Domestic manufactured	Human and veterinary medicines	1,000,000 TZS
2	Imported product	Human and veterinary medicines	2,000 USD

6 Withdrawal of Marketing Authorization

Withdrawn of Marketing Authorization is done in two cases:

1. Voluntary withdrawal (withdrawal initiated by marketing authorization holder)
2. Mandatory withdrawal (withdrawal initiated by the Authority)

7 Pharmacovigilance System

7.1 National Pharmacovigilance Centre (NPC):

- Central hub for monitoring drug safety.
- Coordinates zone centers for regional activities.

- **Key Functions**:

- Data collection, monitoring, analysis, and signal detection.
- Advising on safety-related matters via the Pharmacovigilance Technical Committee.

Key Responsibilities

- Manufacturers & Marketing Authorization Holders:
- Establish pharmacovigilance systems for ADR reporting.
- Maintain quality systems for good vigilance practices.
- Pharmacovigilance Technical Committee:
- Advises on causality assessment of ADRs.

Recommends technical actions to the Director General.

7.2 Quality System Requirements

- Designated pharmacovigilance contact.
- Record management system for accurate reporting.
- Document control for processes.
- Continuous training on systems and infrastructure.
- Policies for ongoing data monitoring and risk assessment.
- Procedures for effective communication.

7.3 Pharmacovigilance Inspections

- **Scope:**

- Facilities, records, pharmacovigilance systems, and master files.
- Announced/unannounced, routine, and "for cause" inspections.

- **Key Focus Areas:**

- Compliance with regulatory requirements.
- Accuracy and completeness of safety reports.
- **Outcome:** Corrective actions for non-compliance.

7.8 Risk Management System

- **Requirements:**

- Implemented by manufacturers and marketing authorization holders.
- Prompt reporting of significant adverse events.
- Case management for accurate and comprehensive ADR handling.
- **Follow-Up:** Reclassification and accelerated reporting if needed.

7.9 Safety Update Reports

- **Periodic Safety Update Reports (PSURs):**

- Quarterly submissions for risk-benefit evaluation.
- Includes sales data, ADR reports, and scientific analysis.
- Every 6 Months for two years, yearly for next two years and every three years thereafter.

- **Development Safety Update Reports (DSURs):**

- Required for drugs under development or additional research.
- Covers safety data from clinical trials (Phases I–IV).

REFERENCES

1. The Tanzania Food, Drugs and Cosmetics (Pharmacovigilance) Regulations, 2018
2. TMDA variations guidelines march 2020.
3. Guideline on Submission of Documentation for Renewal of Registration of Human and Veterinary Pharmaceutical Products.
4. Guidelines on Submission of Documentation for Registration of Human Pharmaceutical Products
5. National Guidelines for Monitoring Medicines Safety
6. The Tanzania Medicines and Medical Devices (Pharmacovigilance) Regulations.

HOW TO CITE: Rutanshi Patel*, Gargi Patel, Dr. Maitreyi N. Zaveri, Zuki Patel, Strategic Insights into Drug Regulatory Affairs: Dossier Preparation, Marketing Authorization, Variation and Safety Monitoring in Tanzania, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 4, 430-436. https://doi.org/10.5281/zenodo.15132665